In Singapore, data from the national Department of STI Control (DSC) Clinic reveals a stark reality: men who have sex with men (MSM) seeking care there face a syphilis rate that is 25 times higher than the average rate of syphilis. This single statistic anchors a much larger story: the quiet resurgence of a centuries-old bacterial infection. Globally, syphilis is on the rise, presenting a significant public health challenge that has spurred a search for new prevention tools beyond traditional methods. This context has set the stage for a critical debate around a promising but complex intervention: doxycycline post-exposure prophylaxis, or Doxy-PEP.

How Doxy-PEP is Changing STI Prevention

Doxy-PEP is a novel biomedical strategy that involves taking a 200mg dose of the antibiotic doxycycline within 72 hours of condomless sex to prevent bacterial sexually transmitted infections (STIs). Unlike HIV PrEP (Pre-Exposure Prophylaxis), which is taken before potential exposure, Doxy-PEP is taken after. Its emergence marks a significant shift in sexual health, offering an effective, patient-controlled prevention method.

How a Common Antibiotic Became a Prevention Powerhouse

Doxycycline is a broad-spectrum antibiotic that has been used for decades to treat infections. It works by inhibiting bacterial protein synthesis, effectively stopping pathogens from replicating. Seminal clinical trials, such as the IPERGAY and DoxyPEP studies, have demonstrated its high efficacy. A meta-analysis of such trials showed it can reduce the risk of acquiring syphilis by over 75% and chlamydia by over 65% in high-risk populations of MSM and transgender women. Its effectiveness against gonorrhoea, however, is notably lower and more variable due to pre-existing antibiotic resistance.

The Singapore Model: A Tale of Two Strategies

While international trials prove Doxy-PEP works, the crucial question for any country is how to implement it. Should it be offered broadly to a large population, or targeted specifically to those at the highest risk? A groundbreaking behavioural transmission-dynamic modelling study, calibrated with epidemiological data from Singapore, provides a clear, data-driven answer to this question. The study, published as a preprint on medRxiv, projected the long-term public health impact and efficiency of two distinct prescribing strategies over a 15-year period.

The Wide Net vs. The Surgical Scalpel

To understand the study’s findings, it helps to use an analogy. Imagine public health officials are trying to remove a specific type of invasive fish from a large bay.

• The Broad Strategy (The Wide Net): This approach is like dragging a giant net across the entire bay. You would offer Doxy-PEP to all MSM attending a sexual health clinic. This method catches a very large number of the target fish (prevents many syphilis cases), but it also catches thousands of other marine creatures (involves giving prescriptions to many people who wouldn’t have been infected anyway). It’s impactful but incredibly inefficient and potentially disruptive to the ecosystem (by driving antibiotic resistance).
• The Targeted Strategy (The Surgical Scalpel): This is like using a specific lure in a known hotspot where the invasive fish congregate. You would offer Doxy-PEP only to MSM at the precise moment they are diagnosed with syphilis, an event that clearly marks them as being at high risk. This method catches fewer fish overall, but nearly every catch is the one you intended, making it a highly efficient and resource-conscious approach that preserves the health of the bay.

What the Data Projects for Singapore

The modelling study’s projections for Singapore vividly illustrate this trade-off:

• Broad Strategy: This approach was projected to avert the greatest number of infections, an estimated 24,700 syphilis cases. However, its efficiency was extraordinarily low, averting just 0.02 cases for every prescription issued. This implies massive over-prescription.
• Targeted Strategy: This strategy was projected to avert a smaller but still substantial 10,000 cases. Its crucial advantage was its vastly superior efficiency, averting 2.50 cases per prescription. This makes it over 100 times more efficient than the broad approach.

These findings strongly suggest that for Singapore, a targeted strategy is the most sensible and sustainable path. It ensures the intervention reaches those who will benefit most, maximising public health impact per dose while minimising unnecessary antibiotic exposure.

Preventing STIs vs. Fuelling Resistance

The single greatest concern surrounding Doxy-PEP is its potential to accelerate antimicrobial resistance (AMR), a global health crisis. Widespread antibiotic use creates evolutionary pressure that allows resistant bacteria to thrive. This risk is not theoretical; it is a certainty that must be managed. A responsible Doxy-PEP programme must acknowledge and monitor this trade-off.

Gonorrhoea: The Canary in the Coal Mine

Neisseria gonorrhoeae serves as a real-world warning for the AMR risks of Doxy-PEP. This bacterium is already known for its ability to develop resistance. In cities with early Doxy-PEP adoption, surveillance has shown a dramatic increase in tetracycline-resistant gonorrhoea isolates. This demonstrates that Doxy-PEP actively selects for resistant strains in the community, highlighting the absolute necessity of robust surveillance as part of any implementation plan.

Charting a Prudent Path for Doxy-PEP in Singapore

The evidence converges on a clear recommendation: Singapore should consider a formal, targeted Doxy-PEP implementation programme. The current ad-hoc system, where access depends on private clinics and a patient’s own resources, is neither equitable nor safe for long-term public health management.

A responsible programme would offer Doxy-PEP to MSM and transgender women who have had a bacterial STI in the past year, using a recent diagnosis as a reliable indicator of high risk. Crucially, this should not be a standalone prescription. It must be integrated into a comprehensive sexual health framework that includes regular STD testing, linkage to HIV PrEP or HIV care, vaccinations, and ongoing counselling. By adopting a targeted, integrated, and closely monitored approach, Singapore can leverage the power of Doxy-PEP to combat rising syphilis rates while exercising the prudent antibiotic stewardship essential for our collective health security.

Frequently Asked Questions about Doxy-PEP

Is Doxy-PEP a replacement for condoms or HIV PrEP?

No. Doxy-PEP is an additional tool and does not replace other prevention methods. It does not prevent viral infections like HIV, mpox, or herpes. Condoms remain a cornerstone of STI prevention, and HIV PrEP is highly effective specifically for preventing HIV. Doxy-PEP should be used as part of a comprehensive sexual health strategy.

Who is the ideal candidate for Doxy-PEP?

Based on clinical guidelines and the Singapore modelling study, the ideal candidates are individuals at high risk of bacterial STIs. This is often defined as MSM or transgender women who have had at least one diagnosed case of syphilis, chlamydia, or gonorrhoea in the past 12 months. A consultation at an STD clinic can help determine if Doxy-PEP is a suitable option.

What are the main side effects of Doxy-PEP?

The most common side effects of doxycycline are gastrointestinal issues like nausea and oesophageal irritation, which can be minimised by taking the pill with a full glass of water and remaining upright. It can also cause photosensitivity, making the skin more sensitive to the sun. More significant side effects are rare, but should be discussed with a doctor.